Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Jul 15, 2026
Zebra Technologies (ZBRA) Rises +8% Post-Earnings: Key Factors for Investors to Consider

Zebra Technologies (ZBRA) Rises +8% Post-Earnings: Key Factors for Investors to Consider

Key Takeaways

  • Zebra Technologies shares have risen approximately 8% over the past 30 days, reflecting post-earnings strength moderated by recent profit-taking.
  • Q1 2026 results delivered a significant upside: non-GAAP EPS of $4.75 beat consensus estimates of $4.21, while revenue climbed 14.3% year-over-year to $1.50 billion.
  • Management raised full-year 2026 guidance, now projecting adjusted EPS of $18.30–$18.70 and net sales growth of 10–14%.
  • Analyst consensus remains a "Moderate Buy" with an average price target around $325–$333, implying potential upside above recent trading levels.
  • Institutional ownership remains exceptionally high at over 91%, underscoring sustained conviction among large investors.
  • Upcoming Q2 2026 results, anticipated around early August, represent the next major catalyst for the stock.

Where ZBRA Stands in the Market Today

Zebra Technologies Corporation (ZBRA) closed at $260.11 on July 14, 2026, capping a 30-day period in which the stock gained roughly 8.4% from its June 15 close of $240.05. The shares reached an intraday high above $276 in early July before pulling back amid broader sector rotation and light profit-taking. With a market capitalization near $12.4 billion and a price-to-earnings ratio around 31–32, ZBRA trades in the middle of its 52-week range of $199.05 to $352.66. The stock's beta of approximately 1.60 indicates above-average sensitivity to broader market swings, a characteristic that has been on display during the uneven recovery in industrial technology names throughout 2026.

Zebra’s Business Model and Competitive Edge

Zebra Technologies is a global leader in enterprise asset intelligence, providing the hardware, software, and services that enable organizations to digitize and automate frontline workflows. The company operates through two reportable segments: Connected Frontline, which encompasses rugged mobile computers, tablets, and interactive kiosks; and Asset Visibility & Automation, which includes barcode and RFID printers, scanners, machine vision systems, and consumable supplies. Zebra serves a diverse customer base spanning retail, healthcare, manufacturing, transportation, and logistics. Strategic acquisitions—including the $1.3 billion purchase of Elo Holdings in late 2025 and the acquisition of Photoneo for 3D machine vision technology—have broadened its product portfolio and deepened its reach into self-service kiosks and AI-driven industrial automation. With an installed base distributed across more than 10,000 channel partners in 179 countries, Zebra benefits from a recurring revenue stream in high-margin consumables and aftermarket services.

What Drove Recent Moves in ZBRA

The most significant event shaping ZBRA's recent trajectory was the release of first-quarter 2026 results on May 12. The company delivered non-GAAP earnings of $4.75 per share, handily exceeding the Zacks Consensus Estimate of $4.21. Revenue of $1.50 billion also topped expectations, driven by broad-based growth across both segments and all geographic regions. Organic net sales increased 4.3%, with Asia-Pacific leading at 11% organic growth. Adjusted EBITDA margin expanded 90 basis points to 23.2%, reflecting improved operating leverage and favorable business mix.

Following the beat, multiple Wall Street firms raised their price targets. Robert W. Baird lifted its target to $310, while Citi moved to $306 in mid-July. Wolfe Research and TD Cowen reiterated bullish stances with targets of $317 and $400, respectively. On the product front, Zebra showcased its expanded machine vision and automation ecosystem at Automate 2026, debuting the CV70 CXP high-performance camera for semiconductor and EV battery inspection. The company also launched AI-powered platforms—Zebra Nucleus and Workcloud Business Intelligence dashboards—at its ZONE 2026 customer conference. Meanwhile, Zebra executed $300 million in share repurchases during Q1 and an additional $200 million in Q2, signaling confidence in its financial position. Some insider selling was recorded in May, with a director and an executive trimming positions, though overall insider ownership remains modest at under 1%.

2026 Outlook and What Investors Should Watch

Zebra Technologies enters the second half of 2026 with strong operational momentum. Management's Q2 guidance calls for net sales growth of 14–17% year-over-year and adjusted EPS of $4.20–$4.50, with an adjusted EBITDA margin slightly above 21%. Full-year free cash flow is projected to reach at least $900 million. The next critical checkpoint is the Q2 earnings report, currently estimated for early August, which will test whether demand trends in manufacturing and logistics remain durable. Key factors to monitor include memory cost pressures and their impact on margins, the pace of organic growth in the Asset Visibility & Automation segment, progress integrating the Elo and Photoneo acquisitions, and broader macroeconomic signals affecting enterprise capital expenditure. Additionally, any developments around tariff policies—including potential recoveries from previously invalidated IEEPA tariffs—could provide incremental upside. While analyst sentiment remains broadly constructive, sustained execution across product lines and geographies will be essential for ZBRA to close the gap toward consensus price targets.

Exploring Data-Driven Perspectives with Tickeron Tools

For traders seeking data-driven insights beyond traditional stock analysis, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading robots that collectively monitor thousands of tickers across multiple exchanges, but only those bots demonstrating the strongest real-time performance and highest relevance appear in this trending section. Each bot operates with its own distinct strategy, timeframe, and risk profile—ranging from short-term momentum models to longer-horizon trend-following systems—allowing traders to identify approaches aligned with their individual goals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Exploring the Trending AI Robots page can provide an additional layer of quantitative perspective when evaluating stocks like Zebra Technologies.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ZBRA

ZBRA sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ZBRA moved above the 200-day moving average on July 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on ZBRA as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ZBRA just turned positive on July 28, 2026. Looking at past instances where ZBRA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ZBRA advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 147 cases where ZBRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZBRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ZBRA broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ZBRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.181) is normal, around the industry mean (7.453). P/E Ratio (34.478) is within average values for comparable stocks, (69.126). Projected Growth (PEG Ratio) (0.697) is also within normal values, averaging (1.191). ZBRA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (3.205) is also within normal values, averaging (14.864).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZBRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are Cisco Systems (NASDAQ:CSCO), Hewlett Packard Enterprise Company (NYSE:HPE), Lumentum Holdings (NASDAQ:LITE), Ciena Corp (NYSE:CIEN), Nokia Corp (NYSE:NOK), Ericsson (NASDAQ:ERIC).

Industry description

The Telecommunications Equipment industry produces voice and data communications equipment, which includes fiber optic delivery products, digital signal processors, high-speed voice, data and video delivery. Additionally, satellite systems, global positioning systems, wireless data systems, personal communications equipment, telephone handsets and payload equipment for satellites also fall into this category. Apple Inc., QUALCOMM Incorporated and Nokia are major global players in this segment.

Market Cap

The average market capitalization across the Telecommunications Equipment Industry is 22.11B. The market cap for tickers in the group ranges from 1.59K to 478.61B. CSCO holds the highest valuation in this group at 478.61B. The lowest valued company is ABILF at 1.59K.

High and low price notable news

The average weekly price growth across all stocks in the Telecommunications Equipment Industry was 12%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 29%. CLRO experienced the highest price growth at 127%, while INSG experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Telecommunications Equipment Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 53
Price Growth Rating: 47
SMR Rating: 74
Profit Risk Rating: 75
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
ZBRA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a laser printing developer

Industry TelecommunicationsEquipment

Profile
Details
Industry
Computer Peripherals
Address
3 Overlook Point
Phone
+1 847 634-6700
Employees
9750
Web
https://www.zebra.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.